Abstract: Exemplary systems, methods and computer-accessible medium according to exemplary embodiments of the present disclosure can be used to implement a zero-copy data-coherent shared-memory IPC data exchange mechanism. The exemplary procedures, systems, computer accessible medium and/or methods can operate standalone or in combination with underlaying IPC tools. When combined with underlying tools, the exemplary systems, methods and computer-accessible medium does not need to implement the same IPC tool standard. The exemplary procedures, system and/or methods can implement an IPC tool in its entirety, or partially, and it can add functionality to existing IPC tools. The exemplary procedures, system and/or methods can implement a shared memory buffer mechanism, where both a sender process and a receiver process use the same shared memory space.

Abstract: This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to glioma-associated oncogene (Gli) expression. More particularly, this disclosure relates to bicyclic compounds and pharmaceutical compositions thereof, methods of inhibiting Gli expression with these compounds, and methods of treating diseases related to Gli expression.

Abstract: This application provides methods of inhibiting an inflammation- or hypoxia-induced death of a cell involving inhibiting an RNF213 signaling pathway. The application further provides methods of preventing or treating various diseases and disorders in a subject involving administering to the subject an inhibitor of expression of RNF213 protein or an inhibitor of one or more functions of the RNF213 protein. The application still further provides methods for enhancing the effectiveness of a cancer treatment in a subject where the cancer involves a hypoxic tumor microenvironment involving co-administering the cancer treatment with an inhibitor or activator of different functions of the RNF213 protein. The application also provides methods of eliminating drug-resistant tumor cells by co-administering an inhibitor of the expression of RNF213 protein or by inhibiting or activating specific functions of the RNF213 protein.

Abstract: A system includes an eye tracker having a camera, the eye tracker being configured and arranged to track an eye movement of a subject, and a processor in communication with the eye tracker, the processor being configured and arranged to create a dataset of the eye movement, generate a plot of the dataset, the plot reflecting a timecourse of eye position versus time, and identify one or more streaking vertical lines in the plot to indicate a deficit in cranial nerve II function.

Abstract: A process for charging a discharged electrochemical cell includes applying a voltage bias to the discharged electrochemical cell; and illuminating the cathode, the anode, or both the cathode and the anode with light having a narrow band of wavelengths corresponding to the respective band gaps of the electrode active materials.

Abstract: The present invention relates to compounds of Formula (I): where R1, R2, X, s, and p are as defined herein. The present invention also relates to compounds of Formula (II), Formula (III), and: where R1a, R1b, R1d, R2a, R2b, R3b, X, Z, Z1, Z2, s, and p are as defined herein. Methods of using these compounds to regulate Cav2.2.target double-stranded RNA and to treat diseases and disorders, e.g., chronic pain, are also disclosed.

Abstract: Exemplary system, method and computer-accessible medium, according to exemplary embodiments of the present disclosure, can be used to couple, connect, associate, combine, link, or integrate inter-process communication tools (e.g., underlying inter-process communication (IPC) tools), and provide applications with a coupled IPC API (“application programming interface”), potentially different from that of the underlying IPC tools it relies upon. The exemplary procedures, system and/or methods can differentiate between the IPC API provided to an application by the present disclosure, and the IPC API(s) of the underlying tool(s) that is (are) being coupled to. The exemplary procedures, system and/or methods can integrate IPC tools when, e.g.

Abstract: A system includes one or more processors and one or more memories having instructions stored thereon which, when executed by the one or more processors, cause the one or more processors to perform operations include receiving detected ocular landmarks in a subject, determining ocular parameters based on the detected ocular landmarks, and determining, based on the ocular parameters, a coarse calibration output. The operations include receiving, eyetracking data relating to an eye movement made by the subject, determining a landing position of the eye at the end of the eye movement, sending a signal to display a target at the landing position on a screen, and receiving, from the subject, an input including a response relating the landing position to a gaze parameter of the subject. The gaze parameter is associated with the eye movement. The operations include updating the coarse calibration output based on the input.

Abstract: The present invention relates methods for treating cancer by comprising administering to the subject an agent for reducing at least one NEAA, inhibiting the PPP pathway, inhibiting the sorbitol pathway, inhibiting heme biosynthesis, or any combination thereof. The invention also includes methods of treating cancer comprising detecting a tumor as having increased ROS administering to the subject an agent for reducing at least one NEAA, inhibiting the PPP pathway, inhibiting the sorbitol pathway or inhibiting heme biosynthesis, or any combination thereof.

Abstract: The application relates to methods of diagnosis of status epilepticus (SE) or new onset refractory status epilepticus (NORSE), as well as determining the likelihood of mortality associated with SE and/or NORSE, based on mammalian gastrointestinal (GI) microbiota. The application further relates to the treatment or prevention of SE and/or NORSE, or mortality associated with these conditions via use of probiotics, prebiotics, compounds and/or compositions for modulating the GI microbiota.

Abstract: A holographic imaging system comprises an imaging light source defining an imaging light path, an active light source defining an active light path directed at a target, and a polarizer configured to modify the polarization of the active light path. The system further comprises a polarization beam splitter positioned in the active light path and the imaging light path, configured to separate the active light path and the imaging light path, and a photodetector positioned at a terminus of the active light path. The photodetector is configured to measure a reflection of the active light source. A method of holographic imaging is also described.

Abstract: A sensor having a plurality of sensing elements which sense six degrees of freedom of force on a touch layer. The sensor includes a computer which causes prompting signals to be sent to the sensing elements and reconstructs six degrees of freedom of force on the layer from data signals received from the sensing elements. A method for sensing forces. A robotic hand. having a finger having a tip with sensors on the tip. Alternatively, the sensor includes a ribbon cable.

Abstract: A method, apparatus, and system with physical property prediction inference and/or training is provided. A processor-implemented method includes predicting physical properties of a target material using a machine learning model provided an input that is based on a target feature vector, where the target feature vector corresponds to the target material, where the machine learning model is configured to predict the physical properties of the target material based on a multi-dimensional space that is dependent on feature vectors representing respective structures of materials and relation information between the materials.

Abstract: Disclosed herein is a method of inhibiting T Follicular Helper (TFH) cell-mediated differentiation and/or activation in a subject. This method involves administering to a subject in need of treatment for an autoimmune disorder a eukaryotic translation initiation factor 4E (eIF4E) inhibitor to inhibit TFH cell-mediated differentiation and/or activation in the subject. Also disclosed is a method of inhibiting T Follicular Helper (THF) cell differentiation or TFH cell activity.

Abstract: The method of performing braiding operations can include providing a first Josephson junction including first gates. The method can include providing a second Josephson junction including second gates. The method can include tuning the first gates to dispose a first pair of Majorana fermions a first region. The method can include tuning the second gates to dispose a second pair of Majorana fermions in a second region. The method can include tuning the first gates to dispose a first Majorana fermion in the first region and to dispose a second Majorana fermion in a third region. The method can include tuning the second gates to dispose a third Majorana fermion in a fourth region and to dispose a fourth Majorana fermion in the second region.

Abstract: A platform technology provides particle and nucleic acid conjugates, and compositions thereof, with enhanced targeting to cells, tissues, organs. The particles and nucleic acids and other deliverables contain a synthetic binding protein such as a polypeptide monobody covalently conjugated to the surface of the particle or the nucleic acid, for linking a targeting agent to the particle's surface or the nucleic acid. The particles and nucleic acids and other deliverables optionally contain an antibody non-covalently conjugated to the binding protein, via an Fc domain of the antibody. The particles can include therapeutic agents, diagnostic agents, prophylactic agents, or a combination thereof, to be delivered to desired cells, tissues, and/or organs. The particles and nucleic acids and other deliverables can be used in a wide array of applications including, but not limited to, ex vivo perfusion of mammalian organs and in vivo disease treatment.

Abstract: The present disclosure is directed to single domain antibodies that bind to ?-synuclein and the use of these antibodies for the treatment and diagnosis of ?-synucleinopathies The present disclosure is also directed to polynucleotides encoding the ?-synuclein single domain antibodies, therapeutic vectors comprising these polynucleotides and methods of administering these therapeutic vectors for the treatment of ?-synucleinopathies.

Abstract: Embodiments of recombinant HIV-1 gp120 proteins that contain a V1 deletion are disclosed. Also provided are gp140, gp145, and gp160 proteins containing the V1 deletion, as well as HIV-1 Env ectodomain trimers containing protomers containing the V1 deletion. Nucleic acid molecules encoding these proteins are also provided. In several embodiments, the disclosed recombinant HIV-1 proteins and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject, for example, to treat or prevent an HIV-1 infection in the subject.

Abstract: One embodiment relates to a method that includes receiving input data. The input data includes data from a plurality of modalities including imaging or sensing modalities. The method includes processing the input data with a neural network trained to identify shared characteristics among the plurality of modalities. The neural network distills the input data to generate a representation. The method includes processing the representation with the neural network to generate an output.

Abstract: A method for computation with recurrent neural networks includes receiving an input drive and a recurrent drive, producing at least one modulatory response; computing at least one output response, each output response including a sum of: (1) the input drive multiplied by a function of at least one of the at least one modulatory response, each input drive including a function of at least one input, and (2) the recurrent drive multiplied by a function of at least one of the at least one modulatory response, each recurrent drive including a function of the at least one output response, each modulatory response including a function of at least one of (i) the at least one input, (ii) the at least one output response, or (iii) at least one first offset, and computing a readout of the at least one output response.